SIGA Technologies Shares Higher After FDA Approves IV TPOXX for Smallpox
May 19 2022 - 9:13AM
Dow Jones News
By Michael Dabaie
SIGA Technologies Inc. shares were up 31% to $9.67 premarket
Thursday after the commercial-stage pharmaceutical company said the
U.S. Food and Drug Administration approved the intravenous
formulation of TPOXX for smallpox.
The IV formulation is an option for those who are unable to
swallow the oral capsules of TPOXX, the company said.
The oral formulation of TPOXX, or tecovirimat, is approved in
the U.S., Canada and Europe for the treatment of smallpox. The
European approval also includes the treatment of monkeypox, cowpox
and complications from immunization.
Dozens of confirmed or suspected cases of monkeypox have
recently been detected in the U.S., U.K., Spain and Portugal. The
World Health Organization says viral disease monkeypox occurs
mainly in tropical rainforest areas of Central and West Africa and
is occasionally exported to other regions. Monkeypox is mostly
transmitted to people from wild animals like rodents and primates,
but human-to-human transmission occurs, World Health Organization
says.
SIGA last week said the U.S. Department of Defense awarded it a
contract for the procurement of up to about $7.5 million of oral
TPOXX.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 19, 2022 08:58 ET (12:58 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Aug 2024 to Sep 2024
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Sep 2023 to Sep 2024